MedTrace Logo

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

NCT00377520 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2009-11-20

Study results available
· View outcomes & findings →

Summary

The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.

Conditions

  • Neoplasms
  • Neoplasms by Site
  • Urogenital Neoplasms
  • Genital Neoplasms, Female
  • Uterine Neoplasms
  • Endometrial Neoplasms
  • Cancer of Endometrium
  • Endometrial Cancer
  • Cancer of the Endometrium
  • Endometrium Cancer
  • Neoplasms, Endometrial

Interventions

DRUG

pemetrexed

900 mg/m2, intravenous (IV), every 21 days, until disease progression

Sponsors & Collaborators

Principal Investigators

  • David Miller, MD · Gynecologic Oncology Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-10-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00377520 on ClinicalTrials.gov